Amoéba is an industrial greentech specializing in the treatment of microbiological risk, developing a biocontrol agent for plant protection in agriculture as well as a range of cosmetic ingredients. The company has announced the results of a clinical study confirming the benefits of using its ingredient in cosmetics for skin care.
In parallel with the development of its biocidal and biocontrol applications, Amoéba has discovered the benefits of amoeba lysate. Willaertia magna C2c Maky for cosmetic applications. This amoeba has been isolated from the environment and has a number of advantages.
An initial clinical study was carried out by the Institute for Clinical Expertise on 30 hemifacial volunteers (n=60) in March and April 2024. According to Amoéba, this study confirms the value of using its ingredient in cosmetics for skin care, with "statistically significant" measured results justifying the following claims:
- "improvement in dermal thickness
- "repairing effect on the superficial dermis".
- "improved skin density
- "improved dermal texture
Amoéba has also obtained the inclusion of this active ingredient on the Inci list, paving the way for commercialization and the search for commercial partnerships without any further authorization.
The skincare market is estimated to be worth $200 billion in 2023, with expected annual growth of 6% per year until 2030 (source: McKinsey). The beauty market in 2023).
Photo taken from the Amoéba website.
